Cardiovascular diseases are the number one cause of death globally.
Worldwide, over 30% of all deaths are attributable to cardiovascular disease (CVD).1 The increasing incidence and high cost of care of CVDs demand a global approach to prevention, early detection & treatment, and monitoring of disease progression. Used in conjunction with clinical information, cardiac biomarkers are crucial to support rapid and accurate diagnosis, especially in acute cases where every minute counts.
As a market leader in cardiac biomarkers, Roche offers diagnostic tests for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF).
In the Middle East, Roche Diagnostics hosts the Middle East’s Cardiovascular Regional Experts Symposium – iCaRE – that brings together leading regional and international experts to share the latest reference points in cardiovascular disease management, as well as best practices and success stories from their fields. At the heart of the discussions were the latest diagnostic methods and tests to detect this non-communicable disease and the participants’ role in their prevention.